Terminated trial tests new combo for tough lung cancers
Disease control
Terminated
This study tested whether adding a new oral drug called HBI-8000 to an existing immunotherapy (pembrolizumab) could help control advanced non-small cell lung cancer. It was designed for adults with a specific biomarker (PD-L1 ≥1%) who had limited prior treatment. The trial was te…
Phase: PHASE2 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC